Drug Detail

Information about Linsitinib

Generic Name
 Linsitinib
IND
 OSI-906
Brand Name (US)
Manufacturer
 OSI
Drug Type
 Tyrosine Kinase Inhibitor
Delivery
 Oral
Approval Status
 Phase 2
Indications
Overall Strategy
 GIST cell based
Strategy
 Block related tumor signal paths
Drug Category
 IGF1R inhibitor

This is a IGF1R inhibitor in early clinical trials for wild-type & pediatric-type GIST. IGF1R is overexpressed about 2/3 of wild-type GISTs. Recent research has suggested overexpression appears to be primarily limited to patients with the various forms of pediatric-like GIST, also known as SDH-deficient GIST.
Patients with pediatric-like GIST may be good candidates for a trial with inhibitors of IGF1R.

Links

 

 Dicovery of OSI-906 a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor
   

 

 OSI-906 from the OSI website
   

 

 LRG article- Oct., 2012 - New developments seen in Pediatric-like GIST
   

 

 LRG article - Aug., 2012 - New gene panel takes mutation testing to a new level. This new 23 gene test is especially good for wild-type GIST as it tests for mutations in the various SDH genes as well as BRAF, HRAS and KRAS.
   

 

 LRG article (as reported by Becky Bensenhaver) - Aug., 2012 - NIH clinic shares information on 3 trials
   

 

 Wildtype GIST & SDH: what to know, by Jennifer Wright. LRG Newsletter article, April, 2011.
   

Trials of this drug

  

 Phase 1 Study of Intermittent OSI-906 Dosing
   

  

 Phase 1 Study of Continuous OSI-906 Dosing
   

  

 Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
   

Trial results
  Linsitinib (OSI-906) for the treatment of Adult and Pediatric Wild Type Gastrointestinal Stromal Tumors, a SARC Phase II study
   
  2015 - A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors
   
  2015 - Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors
   
  ASCO 2010 - Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors.
   
  ASCO 2010 - Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.
   

Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed